R. Ali, Q., Q. Alani, M., N. Abdallha, H., Obaid Al Mawla, S. (2014). Evaluate the prevalence of CCP and RF antibodies as a marker for diagnosis and progression of Rheumatoid Arthritis disease and assess the prevalence of HCV in RA patients. Alustath, 7(2), 1-6. doi: 10.37652/juaps.2013.84963
Qabas R. Ali; Mohammad Q. Alani; Hanaa N. Abdallha; Salim Obaid Al Mawla. "Evaluate the prevalence of CCP and RF antibodies as a marker for diagnosis and progression of Rheumatoid Arthritis disease and assess the prevalence of HCV in RA patients". Alustath, 7, 2, 2014, 1-6. doi: 10.37652/juaps.2013.84963
R. Ali, Q., Q. Alani, M., N. Abdallha, H., Obaid Al Mawla, S. (2014). 'Evaluate the prevalence of CCP and RF antibodies as a marker for diagnosis and progression of Rheumatoid Arthritis disease and assess the prevalence of HCV in RA patients', Alustath, 7(2), pp. 1-6. doi: 10.37652/juaps.2013.84963
R. Ali, Q., Q. Alani, M., N. Abdallha, H., Obaid Al Mawla, S. Evaluate the prevalence of CCP and RF antibodies as a marker for diagnosis and progression of Rheumatoid Arthritis disease and assess the prevalence of HCV in RA patients. Alustath, 2014; 7(2): 1-6. doi: 10.37652/juaps.2013.84963

Evaluate the prevalence of CCP and RF antibodies as a marker for diagnosis and progression of Rheumatoid Arthritis disease and assess the prevalence of HCV in RA patients

Journal of University of Anbar for Pure Science
Article 25, Volume 7, Issue 2, August 2013, Pages 1-6    PDF (520.52 K)
Document Type: Research Paper
DOI: 10.37652/juaps.2013.84963
Authors
Qabas R. Ali1; Mohammad Q. Alani* 1; Hanaa N. Abdallha2; Salim Obaid Al Mawla3
1University of Anbar - College of Science
2Health and medical technology college, Foundation of technical education
3Ministry Of Health
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by the presence of autoantibodies like rheumatoid factor (RF). In the last few years, several other autoantibodies have been described of which anti-cyclic citrullinated peptide (CCP) antibody is the most specific. Chronic hepatitis C virus (HCV) has extrahepaticautoimmune properties and a variety of autoantibodies were found in patients with HCV. This study is conductedto evaluate the sensitivity and specificity of Anti-CCP in compare with RF in RA patients and assess their association with severity of the disease and evaluate if HCV have beenone of the infectious agent for rheumatoid arthritis.Sixty blood samples were collected from RA patients and twenty from both apparently healthy group and HCV patients. The serum from each subject was tested for anti- CCP, RF and anti HCV by enzyme- linked immunosorbent assay (ELISA). Estimation of erythrocyte sedimentation rate (ESR) by Westergreen' method was included in this study. The result indicated that anti-CCP postivity for RA patients sera (78.3%), (20%) for HCV patients and (0.0%) for healthy group, it showed highly significant differences in RA group in compare with control group (P<0.005).While the percentage of RF positive was (70%) for patients with rheumatoid arthritis with significant differences and 20% for patients with viral hepatitis type (c) with no significant differences in compare with control group (5%). Results also showed that (1.7%) of patients with rheumatoid arthritis showed positive result to HCV.
Keywords
Diagnostic value; Anti; CCP antibodies; Rheumatoid factor; HCV
References
  1. Frequency of rheumatoid factor among RA cases was (70%) while anti-cyclic citrullinated peptide was (78.33 %). The sensitivity of CCP and specificity were higher than that of RF which made this test (anti-CCP) considered as a good parameter for diagnosis of rheumatoid arthritis.
  2. The increase in RF and CCP means associate with the increase of ESR lead to suggest that anti-CCP is a prognostic indicator for RA progression, although generally not more useful than RF.
  3. There were 20% of HCV patients who had anti-CCP positive and there were 1.7% of RA patients were infected with HCV, which may lead to the suggestion that HCV may be one of the causative agents of RA or it may trigger the progression of RA.
 

REFERANCES

  1. Arnett, F.; Edworthy, S.; Bloch, D.;Mcshane, D.; Fries, J.; et al. (1988). The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.; 31:315-324.
  2. Schaardenburg, D.; Lagaay, A.M.; Otten, H.G. and Breedveld, F.C. (1993). The relation between class-speciWc serum rheumatoid factors and age in the general population. Br J Rheumatol 32:546–549.
  3. Aho, K.; Palusuo, T. and Kurki, P. (1994).  Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum 23:379–387.
  4. Nielen, M. M.  J.; Dirkjan, V. S.; Henk, W. R.; Rob, J. V. S.; Irene, E. V. H.; et al.( 2004). Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50: 380–386.
  5. Kroot, E. J. A.; De Jong B. A. W.; Miek, A. Van L.; Hilde, S.; Frank H. J. Van Den H.; et al. (2001). The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 43: 1831–1835.
  6. Rantapaa-Dahlqvist, S.; De Jong, B.; Berglin, E.; Hallmans, G.;Wadell, G.; et al. (2003). Antibodies against Cyclic citrullinated peptide and IgA rheumatoid factor predict the development of Rheumatoid arthritis. Arthritis Rheum.; 48: 2741-2749.
  7. Steiner,G. and  Smolen , J. (2002) . Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res .; 4 Suppl 2S:15.
  8. Vossenaar, E.; Zendman, A.; Van Venrooij, W. and Pruijn G. (2003). PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. Bioessays; 25:1106–1118.
  9. Schellekens, G.; De Jong, B.;Van den Hoogen, F.; Van de Putte ,L. and Van Venrooij ,W. (1998). Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis specific autoantibodies. J. Clin .Invest. 101:273-281.
  10. Sox, H.C.J. & Liang, M.H. (1986). The erythrocyte sedimentation rate: guidelines for rational use. Ann Intern Med;104(4):515- 23.
  11. Maillefert, J. F.; Muller, G.; Falgarone, G.; Bour, J. B.; Ratovohery, D.; et al. (2002). Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann Rheum Dis; 61:635–637.
  12. Wener, M.H.; Hutchinson, K.; Morishima, C. & Gretch, D.R. (2004). Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 50(7):2305–8.
  13. Lienesch, D.; Morris, R.; Metzger, A.; Debuys, P. & Sherman, K. (2005) Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J Rheumatol 32(3):489–493.
  14. Abdul-Abbas, K. H. (2007). Correlation between rheumatoid arthritis & some cytokines among Iraqi rheumatoid arthritis patients. M.Sc. thesis. College of Health & Medical Technology-Baghdad. Foundation of Technical Education.
  15. Abdallah, N. H.; Al-Thuwani, N.A.; Nadir, I. M. and Al-Badri, K. (2012). Diagnostic value of Anti-CCP antibodies compared with Rheumatoid factor in Rheumatoid arthritis patients. Journal of Anbar University for pure science; 7(1).
  16. Örge, E.; Çefle, A.; Yazıcı, A.; Gürel-Polat, N. and Hulagu, S. (2010). The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis c infection. Rheumatol. Int. 30:485–488.
  17. Nishimura, K.; Sugiyama, D.; Kogata, Y.; Tsuji G; Nakazawa T.; et al (2007). "Metaanalysis : diagnostic accuracy of anti – cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis". Ann intern Med. 146 (11): 797–808.
  18. Kastbom, A.; Strandberg, G.; Lindroos, A. & Skogh, T. (2004). Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis; 63:1085-9.
  19. De-Rycke, L.; Peen, I.; Hoffman, I.; Kruithof, E.; Union, A.; et al. (2004). Rheumatoid factor & Anti-CCP antibodies in Rheumatoid arthritis: diagnostic value, associations with radiological progression rate & extra-articular manifestations. Ann. Rheum. Dis.; 63: 1587-93.
  20. Forslind, K.; Ahlmén, M.; Eberhardt, K.; Hafström, I. and Svensson, B. (2004). Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis; 63:1090–5.
  21. Kroot, E.; de jong, B.; van Leeuwen, M.;Swinkels, H.;van den Hoogen,F.; et al. (2000). The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum.; 43(8): 1831-5.
Statistics
Article View: 187
PDF Download: 166


Journal Management System. Powered by ejournalplus.com